間質性膀胱炎治療薬の世界市場2019-2023

◆英語タイトル:Global Interstitial Cystitis Drugs Market 2019-2023
◆商品コード:IRTNTR30726
◆発行会社(リサーチ会社):Technavio
◆発行日:2019年1月29日
◆ページ数:117
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル、アジア、北米、ヨーロッパ(EMEA)
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥260,000見積依頼/購入/質問フォーム
Five User(5名様閲覧用)USD3,000 ⇒換算¥312,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥416,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はTechnavio社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Technavio社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

当調査レポートでは、間質性膀胱炎治療薬の世界市場について調査・分析し、市場概要、市場環境、間質性膀胱炎治療薬市場規模、種類別(経口治療、膀胱内治療)分析、市場動向、競争環境、主要地域別市場規模(北米、ヨーロッパ、アジアなど)、関連企業情報などを含め、以下の構成でお届け致します。
・エグゼクティブサマリー
・調査範囲・調査手法
・間質性膀胱炎治療薬の世界市場概要
・間質性膀胱炎治療薬の世界市場環境
・間質性膀胱炎治療薬の世界市場動向
・間質性膀胱炎治療薬の世界市場規模
・間質性膀胱炎治療薬の世界市場:業界構造分析
・間質性膀胱炎治療薬の世界市場:種類別(経口治療、膀胱内治療)
・間質性膀胱炎治療薬の世界市場:地域別市場規模・分析
・間質性膀胱炎治療薬の北米市場規模・予測
・間質性膀胱炎治療薬のヨーロッパ・中東・アフリカ市場規模・予測
・間質性膀胱炎治療薬のアジア太平洋市場規模・予測
・間質性膀胱炎治療薬の主要国分析
・間質性膀胱炎治療薬の世界市場:成長要因、課題
・間質性膀胱炎治療薬の世界市場:競争環境
・間質性膀胱炎治療薬の世界市場:関連企業情報(ベンダー分析)
【レポートの概要】

About this market
The advent of gene therapy to drive market growth. Interstitial cystitis is characterized by urinary urgency and frequency, pelvic pain, and nocturia. However, only a few approved treatments are available, and curable treatments for the disease have not been identified yet. Although the etiology of the disease is not fully understood, usually, a bladder affected by interstitial cystitis is characterized by a thin and denuded urothelium. Most of the approved drugs and off-label drugs are small molecules, and they cannot completely cure the disease. Moreover, owing to the side effects and high costs of the available drugs, companies can establish new innovative treatment options such as regenerative therapy and gene therapy that have fewer side effects. Companies are also trying to develop a drug that can completely cure the disease. Technavio’s analysts have predicted that the interstitial cystitis drugs market will register a CAGR of almost 3% by 2023.
Market Overview
Increasing awareness of interstitial cystitis
Although interstitial cystitis is one of the significantly prevalent bladder diseases, many people are unaware of it as most of the symptoms are very similar to other bladder-related diseases. Hence, educating people and making them aware of interstitial cystitis are very important. Many government and non-government organizations are conducting various programs to increase the awareness of the disease.
Lack of approved drugs
The treatment of interstitial cystitis consists of oral therapy and intravesical therapy as the first- and second-line treatment options, respectively. However, no single treatment works for all people with the disease. The treatment is based on the symptoms of each patient. Most of the patients try different treatments (or combinations of treatments) to get rid of the symptoms. Currently, the global interstitial cystitis drugs market has only two approved drugs, ELMIRON and RIMSO-50 (dimethyl sulfoxide). These drugs are proven their efficacy over the symptomatic treatments. However, these drugs are expensive. Therefore, many patients use off-label drugs largely to relieve the symptoms of the disease.
For the detailed list of factors that will drive and challenge the growth of the interstitial cystitis drugs market during the 2019-2023, view our report.
Competitive Landscape
The market appears to be fragmented and with the presence of several companies including Mylan N.V and Pfizer the competitive environment is quite intense. Factors such as the increasing awareness of interstitial cystitis and the advent of gene therapy, will provide considerable growth opportunities to interstitial cystitis drugs manufactures. Bayer AG, Eli Lilly and Company, Johnson & Johnson Services, Mylan N.V, and Pfizer are some of the major companies covered in this report.

【レポートの目次】

PART 01: EXECUTIVE SUMMARY
PART 02: SCOPE OF THE REPORT
• 2.1 Preface
• 2.2 Preface
• 2.3 Currency conversion rates for US$
PART 03: MARKET LANDSCAPE
• Market ecosystem
• Market characteristics
• Market segmentation analysis
PART 04: MARKET SIZING
• Market definition
• Market sizing 2018
• Market size and forecast 2018-2023
PART 05: FIVE FORCES ANALYSIS
• Bargaining power of buyers
• Bargaining power of suppliers
• Threat of new entrants
• Threat of substitutes
• Threat of rivalry
• Market condition
PART 06: MARKET SEGMENTATION BY TYPE
• Market segmentation by type
• Comparison by type
• Oral therapy – Market size and forecast 2018-2023
• Intravesical therapy – Market size and forecast 2018-2023
• Market opportunity by type
PART 07: CUSTOMER LANDSCAPE
PART 08: GEOGRAPHIC LANDSCAPE
• Geographic segmentation
• Geographic comparison
• North America – Market size and forecast 2018-2023
• Europe – Market size and forecast 2018-2023
• Asia – Market size and forecast 2018-2023
• ROW – Market size and forecast 2018-2023
• Key leading countries
• Market opportunity
PART 09: DRIVERS AND CHALLENGES
• Market drivers
• Market challenges
PART 10: MARKET TRENDS
PART 11: VENDOR LANDSCAPE
• Overview
• Landscape disruption
• Competitive scenario
PART 12: VENDOR ANALYSIS
• Vendors covered
• Vendor classification
• Market positioning of vendors
• Bayer AG
• Eli Lilly and Company
• Johnson & Johnson Services, Inc.
• Mylan N.V.
• Pfizer Inc.
PART 13: APPENDIX
• Research methodology
• List of abbreviations

Exhibit 01: Years in consideration
Exhibit 02: Global pharmaceuticals market
Exhibit 03: Segments of global pharmaceuticals market
Exhibit 04: Market characteristics
Exhibit 05: Market segments
Exhibit 06: Market definition – Inclusions and exclusions checklist
Exhibit 07: Market size 2018
Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
Exhibit 10: Five forces analysis 2018
Exhibit 11: Five forces analysis 2023
Exhibit 12: Bargaining power of buyers
Exhibit 13: Bargaining power of suppliers
Exhibit 14: Threat of new entrants
Exhibit 15: Threat of substitutes
Exhibit 16: Threat of rivalry
Exhibit 17: Market condition – Five forces 2018
Exhibit 18: Type – Market share 2018-2023 (%)
Exhibit 19: Comparison by type
Exhibit 20: Oral therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 21: Oral therapy – Year-over-year growth 2019-2023 (%)
Exhibit 22: Intravesical therapy – Market size and forecast 2018-2023 ($ millions)
Exhibit 23: Intravesical therapy – Year-over-year growth 2019-2023 (%)
Exhibit 24: Market opportunity by type
Exhibit 25: Customer landscape
Exhibit 26: Market share by geography 2018-2023 (%)
Exhibit 27: Geographic comparison
Exhibit 28: North America – Market size and forecast 2018-2023 ($ millions)
Exhibit 29: North America – Year-over-year growth 2019-2023 (%)
Exhibit 30: Top 3 countries in North America
Exhibit 31: Europe – Market size and forecast 2018-2023 ($ millions)
Exhibit 32: Europe – Year-over-year growth 2019-2023 (%)
Exhibit 33: Top 3 countries in Europe
Exhibit 34: Asia – Market size and forecast 2018-2023 ($ millions)
Exhibit 35: Asia – Year-over-year growth 2019-2023 (%)
Exhibit 36: Top 3 countries in Asia
Exhibit 37: ROW – Market size and forecast 2018-2023 ($ millions)
Exhibit 38: ROW – Year-over-year growth 2019-2023 (%)
Exhibit 39: Top 3 countries in ROW
Exhibit 40: Key leading countries
Exhibit 41: Market opportunity
Exhibit 02: Funds for research on interstitial cystitis
Exhibit 03: Overlapping of the symptoms of interstitial cystitis
Exhibit 04: Impact of drivers and challenges
Exhibit 05: Strategic alliances in the global interstitial cystitis drugs market
Exhibit 06: Vendor landscape
Exhibit 07: Landscape disruption
Exhibit 08: Vendors covered
Exhibit 09: Vendor classification
Exhibit 10: Market positioning of vendors
Exhibit 11: Bayer AG – Vendor overview
Exhibit 12: Bayer AG – Product segments
Exhibit 13: Bayer AG – Organizational developments
Exhibit 14: Bayer AG – Geographic focus
Exhibit 15: Bayer AG – Segment focus
Exhibit 16: Bayer AG – Key offerings
Exhibit 17: Bayer AG – Key customers
Exhibit 18: Eli Lilly and Company – Vendor overview
Exhibit 19: Eli Lilly and Company – Business segments
Exhibit 20: Eli Lilly and Company – Organizational developments
Exhibit 21: Eli Lilly and Company – Geographic focus
Exhibit 22: Eli Lilly and Company – Segment focus
Exhibit 23: Eli Lilly and Company – Key offerings
Exhibit 24: Eli Lilly and Company – Key customers
Exhibit 25: Johnson & Johnson Services, Inc. – Vendor overview
Exhibit 26: Johnson & Johnson Services, Inc. – Business segments
Exhibit 27: Johnson & Johnson Services, Inc. – Organizational developments
Exhibit 28: Johnson & Johnson Services, Inc. – Geographic focus
Exhibit 29: Johnson & Johnson Services, Inc. – Segment focus
Exhibit 30: Johnson & Johnson Services, Inc. – Key offerings
Exhibit 31: Johnson & Johnson Services, Inc. – Key customers
Exhibit 32: Mylan N.V. – Vendor overview
Exhibit 33: Mylan N.V. – Business segments
Exhibit 34: Mylan N.V. – Organizational developments
Exhibit 35: Mylan N.V. – Geographic focus
Exhibit 36: Mylan N.V. – Key offerings
Exhibit 37: Mylan N.V. – Key customers
Exhibit 38: Pfizer Inc. – Vendor overview
Exhibit 39: Pfizer Inc. – Business segments
Exhibit 40: Pfizer Inc. – Organizational developments
Exhibit 41: Pfizer Inc. – Geographic focus
Exhibit 42: Pfizer Inc. – Segment focus
Exhibit 43: Pfizer Inc. – Key offerings
Exhibit 44: Pfizer Inc. – Key customers
Exhibit 45: Validation techniques employed for market sizing
Exhibit 46: List of abbreviations



【掲載企業】

Bayer AG、Eli Lilly and Company、Johnson & Johnson Services、Mylan N.V、and Pfizer

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[間質性膀胱炎治療薬の世界市場2019-2023]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆